The impact of PKD1 expression on the progression of breast cancer has been assessed in vivo. Therefore, mice orthotopically implanted with MDA-MB-231 cells, which only express the oncogenic versions PKD2 and PKD3, were treated with the DNA methyltransferase inhibitor decitabine. This evidence concerns the gene PKD2 and breast cancer.